Azophenols as ERG oncogene inhibitors
US-10238639-B2 · Mar 26, 2019 · US
Azophenols as ERG oncogene inhibitors
US11648239B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11648239-B2 |
| Application number | US-202117158930-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jan 26, 2021 |
| Priority date | Sep 10, 2015 |
| Publication date | May 16, 2023 |
| Grant date | May 16, 2023 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Selective azophenol inhibitors of a wild type or an altered ERG protein expression are described, where the inhibitors represent a compound of Formula (I) or Formula (II)wherein X, X1, X2, X3, X4 and X5, R1 through R4 and R9 are as described.
First claim
Opening claim text (preview).
We claim: 1. A pharmaceutical composition comprising a compound selected from: or a pharmaceutically acceptable salt thereof, and an excipient. 2. The pharmaceutical composition according to claim 1 , wherein the compound is: or a pharmaceutically acceptable salt thereof. 3. The pharmaceutical composition according to claim 1 , wherein the compound is: or a pharmaceutically acceptable salt thereof. 4. The pharmaceutical composition according to claim 1 , wherein the compound is: or a pharmaceutically acceptable salt thereof. 5. The pharmaceutical composition according to claim 1 , wherein the compound is: or a pharmaceutically acceptable salt thereof. 6. The pharmaceutical composition according to claim 1 , wherein the compound is: or a pharmaceutically acceptable salt thereof. 7. The pharmaceutical composition according to claim 1 , wherein the compound is: or a pharmaceutically acceptable salt thereof. 8. The pharmaceutical composition according to claim 1 , wherein the compound is: or a pharmaceutically acceptable salt thereof. 9. The pharmaceutical composition according to claim 1 , further comprising an anti-cancer agent. 10. The pharmaceutical composition according to claim 9 , wherein the anti-cancer agent is for prostate cancer.
Assignees
Inventors
Classifications
Non condensed pyridines; Hydrogenated derivatives thereof · CPC title
Antineoplastic agents · CPC title
- A61K31/426Primary
1,3-Thiazoles · CPC title
only substituted in position 2, e.g. pheniramine, bisacodyl · CPC title
with nitrogen atoms of azo groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11648239B2 cover?
- Selective azophenol inhibitors of a wild type or an altered ERG protein expression are described, where the inhibitors represent a compound of Formula (I) or Formula (II)wherein X, X1, X2, X3, X4 and X5, R1 through R4 and R9 are as described.
- Who is the assignee on this patent?
- Henry M Jackson Found Advancement Military Medicine Inc
- What technology area does this patent fall under?
- Primary CPC classification A61K31/426. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue May 16 2023 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).